Mangi Muhammad A, Rehman Hiba, Rafique Muhammad, Illovsky Michael
GME Internal Medicine, Orange Park Medical Center.
Anesthesiology, Liaquat National Hospital.
Cureus. 2017 Apr 18;9(4):e1174. doi: 10.7759/cureus.1174.
Heart failure (HF) is one of the leading causes of morbidity and mortality and has a large effect on the country's economy. Although there have been major advances in HF monitoring, including more advanced pharmacological management and device-based therapy, HF-related mortality remains high. It is important to monitor HF so that HF-related hospitalization and mortality can be prevented. Due to the lower sensitivity of clinical features and biochemical markers, as well as the failure of telemonitoring in early detection of HF, more advanced techniques have been sought to more accurately predict impending HF, in order to address timely pharmacological management and prevent heart failure hospitalization (HFH). Device-based therapy has passed through various stages and culminated in the recently introduced CardioMEMS (St. Jude Medical, Inc., Saint Paul, Minnesota). CardioMEMS is a wireless pulmonary artery pressure (PAP) monitoring device, which continuously monitors PAP and transmits data to a healthcare provider. It rapidly identifies changes in intracardiac pressure and allows timely pharmacological management. CardioMEMS showed a higher reduction of HFH compared to any other devices.
心力衰竭（HF）是发病和死亡的主要原因之一，对国家经济有重大影响。尽管在HF监测方面取得了重大进展，包括更先进的药物治疗和基于设备的治疗，但与HF相关的死亡率仍然很高。监测HF很重要，这样可以预防与HF相关的住院和死亡。由于临床特征和生化标志物的敏感性较低，以及远程监测在HF早期检测中的失败，人们一直在寻求更先进的技术来更准确地预测即将发生的HF，以便及时进行药物治疗并预防心力衰竭住院（HFH）。基于设备的治疗已经历了各个阶段，并最终发展到最近推出的CardioMEMS（圣犹达医疗公司，明尼苏达州圣保罗）。CardioMEMS是一种无线肺动脉压（PAP）监测设备，它持续监测PAP并将数据传输给医疗服务提供者。它能快速识别心内压的变化，并允许及时进行药物治疗。与任何其他设备相比，CardioMEMS显示出更高的HFH降低率。
